ASX-listed medical device company Optiscan Imaging (ASX: OIL) has ramped-up its efforts to capture the lucrative US healthcare market by participating in several high-profile industry events where it will demonstrate its pioneering imaging technology for precision diagnostics in human and veterinary applications.
The company’s recent showcases and upcoming appearances will shine a light on its state-of-the-art technology as a non-invasive imaging solution, tailored to bridge-the-gap between surgery and pathology.
As part of Optiscan’s commitment to strengthening its foothold in the US, the company recently demonstrated its “ViewnVivo” imaging device at the American College of Veterinary Surgeons Surgery Summit in Phoenix, Arizona.
The ViewnVivo device enables veterinary professionals to achieve live, real-time cellular imaging during diagnostic and surgical procedures—an innovation set to transform precision in veterinary care and eventually in humans.
As a group, they (the events) give American surgeons, pathologists and researchers the opportunity to get up close and personal with our innovative, non-invasive imaging technology offerings that are now well and truly into their development journeys. Optiscan CEO and managing director Dr. Camile Farah
Optiscan’s innovative imaging platform has a wide range of applications spanning from minimally invasive surgery, veterinary medicine all the way through to life sciences and biomedical research.
Optiscan’s US tour is set to continue with three significant events through to the end of the year including the Mayo Clinic Beahrs Surgical Innovation Summit in Rochester, Minnesota on November 7th when Dr. Farah will join a panel titled “Anatomy of a Deal,” discussing Optiscan’s ongoing collaboration with the Mayo Clinic.
The partnership with the Mayo Clinic includes Optiscan’s InVue device in a “know-how” agreement with the renowned Mayo Clinic to co-develop digital laser technology for use in robotic surgery.
The InVue platform is a microscopic medical imaging device that delivers what could be termed an on-the-spot “optical biopsy” without th eneed for an actual biopsy which is often painful. It can provide biopsy-free, slide-free imaging of live single cells in real time during surgery.
The technology could provide tremendous benefits, such as immediate pathology insights within the operating theatre, enabling on-the-spot decision-making, adjusting planned treatment and allowing for more precise surgical outcomes.
A more accurate diagnosis is also likely to reduce the need for follow-up procedures or surgery.
Additionally, Optiscan recently moved into veterinary medicine through a partnership with US-based University of Minnesota to combine its cancer imaging technology with the veterinary faculty’s research expertise with dogs and cats.
The partnership’s goal is to generate clinical data that will prove the worth of Optiscan’s digital confocal laser endomicroscopic imaging system in veterinary medicine, particularly in the diagnosis and treatment of cancer in cats and dogs.
With more than 70 million domesticated dogs and 80 million cats in the US alone, many of them facing significant health issues, the veterinary market presents a unique opportunity for innovation.
Annually, more than 12 million companion animals are diagnosed with cancer, creating a pressing need for improved veterinary services. Among those cases, breast and oral cancers are particularly prevalent, accounting for 27 per cent to 53 per cent of cancer diagnoses in cats and dogs.
The market opportunity aligns well with the conditions Optiscan is already addressing in human oncology, making veterinary medicine a natural extension of its technology.
The move into veterinary services is recent addition for Optiscan, although the idea to do so may have been generated closer to home with Opitscan’s biggest shareholder, Bob Peters – a prominent Western Australian businessman and horse racing identity – who is a long-time supporter of the company following his own personal brush the cancer just 3 years ago.
As Optiscan’s presence in the US grows, so does its reputation as a pioneer in high-resolution, digital pathology solutions that bridge-the-gap between pathology and surgery.
The company will also attend the American College of Veterinary Pathologists Annual Meeting in Seattle, Washington on the 16th of November and The American Society for Cell Biology Annual Meeting in San Diego, California on the 14th of December.
Is your ASX-listed company doing something interesting? Contact: office@bullsnbears.com.au